How do you fund a venture that claims it can create breakthroughs in medical science when it’s not based on science?
You find believers. People who live with the problem you’re trying to solve and deeply understand the need for a new approach. People who want to be a part of a technology venture that matters. People who know you and believe you will make it happen. And even people who just want to see a few women founders succeed.
That’s how we raised our first £2M in grants and angel funding at Quin, and we will definitely be raising more. But over the next few weeks we’re doing something completely different…
We want to reach a very different investor audience. People who may very well have the same motivations as our existing investors, but for whatever reason – timing, social, financial, or otherwise – don’t always get access to opportunities like Quin. If that’s you, we want to invite you to become a Quin shareholder now, before we launch next year.
Breakthroughs are waiting outside the lab
To give you a bit of background on why Quin matters, here are some unfortunate facts about the state of play in insulin-treated diabetes: 92% of 40M people who take insulin do not achieve recommended medical targets, and they are all 2 to 3 times more likely to have fatigue, anxiety, stress and depression.
Imagine this headline on a major industry journal: 92% of people who use our products and services don’t get what they need, and many of them experience serious mental health issues as a result. That wouldn’t be acceptable in any industry.
” It’s been nearly 100 years since the discovery of insulin, and it’s time for a new approach. “
We believe the keys to unlocking new solutions for insulin-treated diabetes are in the hearts and minds of people who take insulin. No one can tell them exactly how much insulin to take and when. They figure it out on their own making hundreds of decisions a day using trial and error.
Quin is a mobile app that combines their daily life experience with data from diabetes devices, wearable sensors and phones and helps them decide how much insulin to take and when.
We are structuring this data to reveal previously unseen insights into the causes behind insulin-treated diabetes and expand diabetes science.
40M people. Roughly 180 decisions per person per day. That’s over 7 billion clues about what diabetes is and how to solve it every day.
Yes, the odds are against us (but the data tells a different story)
We’re making a medical device that’s based on people first, and medical science second. There is no medical science to back up our approach, and there will be none until we create it. There are no benchmarks for investing in medical devices that don’t start with medical science. And we are two women founders, so only 3% of venture capital goes to people like us anyway.
But we’ve got a lot going for us too: 100s of users have been co-developing the Quin app for the past 2 years. 76% of them feel better about living with diabetes, and 35% have improved their HbA1c – healthcare’s target measure. Our team of 12 has 2 patents pending and a European CE Mark as a regulated medical device. We’ve raised £2M in grants and angel funding, and we’ve been granted unprecedented access to engineers and executives at Apple who are helping us get Quin to market.
Citizen science should be backed by citizen investors
We want to find out who else wants to be involved, and invite them to join our community and our shareholder family. If that’s you, next week we’re launching a crowdfunding campaign. We’re aiming to raise funds in 30 days from anyone who wants to own a piece of our people-first solution to a major world health problem.
We’re looking for more believers. Maybe you believe it’s time for a people-centered engineering approach to solving insulin-treated diabetes. Maybe you believe technology should be used to meaningfully improve people’s lives. Or maybe you just believe women entrepreneurs should have equal access to financing and opportunity.
Regardless of what motivates you, your investment, starting from as little as £10, will help our proven team of designers, engineers and product makers make a dent in this major world health problem. We’ll use these funds to fuel the launch of the Quin app in the UK and Europe in late 2020.
You can pre-register your interest now by clicking this link, and we’ll send you the details when we launch our crowd campaign.
We’d love to have you onboard.
When investing in an equity crowdfunding campaign, your capital is at risk.